Evaluation of the Impact of Lock Down and End of Lock Down on the Management of Patients With Inflammatory and Dysimmune Diseases Followed in the Context of IMMINeNT FHU and COVID-19

Evaluation of the Impact of Lock Down and End of Lock Down on the Management of Patients With Inflammatory and Dysimmune Diseases Followed in the Context of IMMINeNT FHU (Rheumatology, Dermatology, Internal Medicine, Pneumology, Gastroenterology, Neurology).

This questionnaire is distributed via a mailing list (e-mail) of patients treated within the framework of the FHU for pathologies including chronic inflammatory bowel diseases or IBD (Crohn's disease and ulcerative colitis), inflammatory rheumatic diseases (such as rheumatoid arthritis and ankylosing spondylitis), but also asthma, psoriasis, atopic dermatitis as well as systemic autoimmune (such as scleroderma, lupus, angioedema) and neurological (multiple sclerosis) diseases.

A two-step analysis will be conducted: impact of lock down(March 17, 2020 - May 11, 2020) and a 2-month assessment of end of lock down (from May 11, 2020) on issues addressing: overall impact, impact on the disease, treatment and follow-up, and access to information related to the epidemic during these periods.

Inclusion Criteria:

patient followed for :

• Chronic inflammatory bowel disease or IBD (Crohn's disease and ulcerative colitis),
• Inflammatory rheumatism (rheumatoid arthritis and spondylitis)
• Multiple Sclerosis
• Asthma
• Psoriasis
• Atopic Dermatitis
• Systemic autoimmune diseases (scleroderma and lupus)

Exclusion Criteria:

• Minor patient
• Patient cannot read or write
• Patient without computer equipment
• Patient with no internet access
• Patient not having filled in his e-mail in his file
• Patient does not wish to be contacted by email